Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

141. Infliximab maintenance therapy for fistulizing Crohn's disease.

Infliximab maintenance therapy for fistulizing Crohn's disease. 14985485 2004 02 26 2004 03 03 2015 11 19 1533-4406 350 9 2004 Feb 26 The New England journal of medicine N. Engl. J. Med. Infliximab maintenance therapy for fistulizing Crohn's disease. 876-85 Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients (...) with fistulas. We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or perianal fistulas of at least three months' duration. Patients received 5 mg of infliximab per kilogram of body weight intravenously on weeks 0, 2, and 6. A total of 195 patients who had a response at weeks 10 and 14 and 87 patients who had no response were then randomly

NEJM2004

142. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. BACKGROUND: Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of these antibodies in patients with Crohn's disease. METHODS: In a cohort of 125 consecutive patients with Crohn's disease who were treated with infliximab infusions, we evaluated the concentrations (...) of infliximab and of antibodies against infliximab, clinical data, side effects (including infusion reactions), and the use of concomitant medications before and 4, 8, and 12 weeks after each infusion. RESULTS: A mean of 3.9 infusions (range, 1 to 17) per patient were administered over a mean period of 10 months. Antibodies against infliximab were detected in 61 percent of patients. The presence of concentrations of 8.0 microg per milliliter or greater before an infusion predicted a shorter duration

NEJM2003

143. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab (...) when added to methotrexate in patients with active rheumatoid arthritis Hochberg M C, Tracy J K, Hawkins-Holt M, Flores R H CRD summary This review compared adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. The authors concluded that the three agents have similar efficacy when combined with methotrexate. Overall, the methods of analysis may mean that the trials were not powered to detect any true treatment effect differences. Head-to-head

DARE.2003

144. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study

The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study Kobelt G, Jonsson L, Young A, Eberhardt K Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the addition of infliximab (Remicade) to methotrexate for the treatment of patients with rheumatoid arthritis (RA). The standard dose prescribed in clinical practice was 3

NHS Economic Evaluation Database.2003

145. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, Burls A Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A, Burls A. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technology Assessment 2003; 7(3): 1-78 Authors' objectives The objectives of the review were to address the following questions: - How effective is infliximab as a second- or third-line

Health Technology Assessment (HTA) Database.2003

146. Infliximab (Anti-TNF-alfa) in treating Crohn´s disease</a>

Infliximab (Anti-TNF-alfa) in treating Crohn´s disease Infliximab (Anti-TNF-alfa) in treating Crohn´s disease We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Infliximab (Anti-TNF-alfa) in treating Crohn´s disease Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed (...) formation. Approximately 13 000 individuals in Sweden have Crohns disease. The number of new cases per year is estimated at 500. Several drugs are currently available to reduce inflammation and ameliorate symptoms. Nevertheless, in approximately 75 percent of the patients, surgical treatment must be used to eliminate inflammation or its effects. The production of TNF-alfa increases in Crohns disease. A new drug, Infliximab (Remicade), was approved in 1999 to treat Crohns disease. The active component

Swedish Council on Technology Assessement2003

147. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2003

148. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Jobanputra P, Barton P, Bryan S, Burls A, Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jobanputra P, Barton P, Bryan S, Burls A,. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(21): 1-110 Authors' objectives This report reviews the evidence for the clinical effectiveness and cost-effectiveness of etanercept

Health Technology Assessment (HTA) Database.2002

149. Guidance on the use of infliximab for Crohn's disease

Guidance on the use of infliximab for Crohn's disease Guidance on the use of infliximab for Crohn's disease Guidance on the use of infliximab for Crohn's disease National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of infliximab for Crohn's disease. London (...) : National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 40. 2002 Authors' objectives To provide guidance on the use of infliximab for Crohn's disease. Authors' conclusions Guidance 1.1 Infliximab is recommended for the treatment of patients with severe Crohn's disease who fulfil all three of the following criteria: - Patients who have severe active Crohn's disease. These patients will already be in very poor general health with weight loss and sometimes fever, severe abdominal

Health Technology Assessment (HTA) Database.2002

150. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis

Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 36. 2002 Authors' objectives To provide guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Authors' conclusions Guidance 1.1 Etanercept and infliximab (infliximab only in combination with methotrexate) are recommended as options

Health Technology Assessment (HTA) Database.2002

151. Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis

Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, Dipchand C, O'Brien B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, Dipchand C, O'Brien B. Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 66 Authors' objectives (1) To review available data supporting the efficacy, effectiveness and adverse effects of infliximab in the treatment

Health Technology Assessment (HTA) Database.2002

152. Clinical and economic assessment: infliximab for the treatment of Crohn's disease

Clinical and economic assessment: infliximab for the treatment of Crohn's disease Clinical and economic assessment: infliximab for the treatment of Crohn's disease Clinical and economic assessment: infliximab for the treatment of Crohn's disease Marshall J K, Blackhouse G, Goeree R, Brazier N, Irvine E J, O'Brien BJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Marshall J K, Blackhouse G, Goeree R, Brazier N, Irvine E J, O'Brien BJ. Clinical and economic assessment: infliximab for the treatment of Crohn's disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 20 Authors' objectives (1) To review available data supporting the efficacy, effectiveness and adverse effects of infliximab in the treatment of patients with Crohn's disease (CD). (2) To conduct a primary cost-utility analysis

Health Technology Assessment (HTA) Database.2002

153. Clinical and economic assessment: infliximab for the treatment of Crohn's disease

Clinical and economic assessment: infliximab for the treatment of Crohn's disease Clinical and economic assessment: infliximab for the treatment of Crohn's disease Clinical and economic assessment: infliximab for the treatment of Crohn's disease Marshall J K, Blackhouse G, Goeree R, Brazier N, Irvine E J, O'Brien B J Authors' objectives To review the available data supporting the efficacy, effectiveness and adverse effects of infliximab in the treatment of patients with Crohn's disease (CD (...) ). Searching MEDLINE, EMBASE, Current Contents, HealthSTAR, TOXLINE, CINAHL and the Cochrane Library were searched from 1990 to 2001; the search terms were reported. This was supplemented with searches of pharmaceutical industry databases and contact with study authors. In addition, gastroenterology journals were handsearched through August 2001 and abstract listings from relevant scientific meetings were searched. Pharmaceutical companies involved in the production and distribution of infliximab were

DARE.2002

154. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Jobanputra P, Barton P, Bryan S, Burls A Authors' objectives The main objective was to assess (...) the clinical benefits and hazards of using etanercept and infliximab in rheumatoid arthritis. Searching MEDLINE (from 1996 to 2001), EMBASE (from 1998 to 2001), the Science Citation Index, the Cochrane Library and the National Research Register were searched; the search terms were provided. Abstracts from relevant conferences, pharmaceutical industry submissions to the National Institute for Clinical Excellence (NICE) and the Food and Drug Administration website were also searched. Study selection Study

DARE.2002

155. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis

Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis Wong J B, Singh G, Kavanagh A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of infliximab, an anti-tumour necrosis factor A drug, for the treatment of rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients suffering from active and refractory RA. Active RA was defined as a combination of synovitis (at least 6 swollen or tender joints) and other symptoms

NHS Economic Evaluation Database.2002

156. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

NIHR HTA programme2002

157. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. 11955536 2002 04 16 2002 04 25 2015 11 19 0140-6736 359 9313 2002 Apr 06 Lancet (London, England) Lancet Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. 1187-93 BACKGROUND Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha (...) , in treatment of such patients. In this 12-week placebo-controlled multicentre study, we randomly assigned 35 patients with active ankylosing spondylitis to intravenous infliximab (5 mg/kg) and 35 to placebo at weeks 0, 2, and 6. One patient in the infliximab group was withdrawn from the study. Our primary outcome was regression of disease activity of at least 50%. To assess response, we used validated clinical criteria from the ankylosing spondylitis assessment working group, including disease activity

Lancet2002

158. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. 12047962 2002 06 05 2002 07 12 2015 11 19 0140-6736 359 9317 2002 May 04 Lancet (London, England) Lancet Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. 1541-9 We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab. 573 patients with a score of at least 220 on the Crohn's (...) disease activity index (CDAI) received a 5 mg/kg intravenous infusion of infliximab at week 0. After assessment of response at week 2, patients were randomly assigned repeat infusions of placebo at weeks 2 and 6 and then every 8 weeks thereafter until week 46 (group I), repeat infusions of 5 mg/kg infliximab at the same timepoints (group II), or 5 mg/kg infliximab at weeks 2 and 6 followed by 10 mg/kg (group III). The prespecified co-primary endpoints were the proportion of patients who responded

Lancet2002

159. Infliximab for the treatment of rheumatoid arthritis.

Infliximab for the treatment of rheumatoid arthritis. BACKGROUND: Infliximab is a human murine chimeric anti-tumour necrosis factor alpha monoclonal antibody recently approved for the treatment of refractory RA. OBJECTIVES: To assess the efficacy and safety of infliximab for the treatment of rheumatoid arthritis. SEARCH STRATEGY: Electronic databases including Biological Abstracts, CINAHL, Current Contents, Dissertation Abstracts, EBM Reviews, HealthSTAR and MEDLINE were searched from 1966 (...) to March 2002. Rheumatoid arthritis was searched as an exploded MESH heading. Infliximab was searched as a text word as it is not currently indexed. The search was not limited by language, year of publication or type of publication. The specific search strategy is shown below. SELECTION CRITERIA: All randomized controlled trials comparing infliximab 1, 3, 5 or 10 mg/kg with methotrexate(MTX) to MTX alone, or without MTX to placebo, with a minimum duration of 6 months and at least 2 infusions were

Cochrane2002

160. Infliximab-induced aseptic meningitis.

Infliximab-induced aseptic meningitis. We report an episode of aseptic meningitis in a 53-year-old man, who was treated with infliximab for active rheumatoid arthritis. He had acute, severe muscle pain after initial infusion of the drug, and similar symptoms with a transient lymphocytic meningitis after a subsequent infusion. We measured no change in antibodies to nuclei, DNA, or to neurones. Functional antibodies to infliximab were not induced and concentrations of tumour necrosis factor (...) a in spinal fluid were not raised. This adverse reaction to infliximab might have been caused by inability of the drug to enter the central nervous system.

Lancet2001